Ask An Audiologist has published a new guide explaining normal hearing range Hz by age, helping readers understand how hearing changes ...

Frequency Therapeutics’ hearing loss treatment showed early signs of efficacy last year, with some patients showing improvements after a few months. Now, as the biotech plugs away at a phase 2a study, ...

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The ...

Once we know what sounds we are hearing and where the sounds are coming from, our brains can begin the complex task of ...

National Correspondent; Anchor, "CBS Weekend News" Jericka Duncan is a national correspondent and anchor of the "CBS Weekend News." She's based in New York City. Chris Sopuch has taught at Oakcrest ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused ...

Frequency Therapeutics (NASDAQ:FREQ) is reducing its workforce by 55% and abandoning programs in Sensorineural Hearing Loss (SNHL) after FX-322 failed to meet the main goal of a phase 2b study in ...

An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...